Pharvaris N.V. Form 4 Filings

Pharvaris N.V. (PHVS) reported that Chief Executive Officer Berndt Modig sold 2,292 shares of common stock on 2026-08-14 at an average price of $34.7669 per share. The shares were acquired upon vesting of restricted stock units and the sale was made pursuant to a Rule 10b5-1 trading plan. Following this transaction, Modig holds 130,625 shares directly and 950,000 shares indirectly through Schoodic Management BV, an entity he controls.

Pharvaris N.V. President Lu Peng reported two code F transactions involving company common stock. On 2026-08-12, 117 shares were withheld at $34.42 per share, and on 2026-08-11, 109 shares were withheld at $34.84 per share. Footnote disclosure states these 226 shares were retained by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units, rather than being sold in open-market transactions. The filing indicates these events were not executed under a Rule 10b5-1 trading plan.

On July 13, 2026, Pharvaris N.V. Chief Executive Officer Berndt Modig executed an open-market sale of 2,292 shares of common stock at a weighted average price of $34.9714, pursuant to a scheduled Rule 10b5-1 trading plan. Following this sale, he holds 132,917 shares directly and 950,000 shares indirectly through Schoodic Management BV.

Pharvaris N.V. Chief Medical Officer Lu Peng reported two tax-withholding dispositions tied to vesting of restricted stock units. The issuer withheld 117 and 109 common shares, totaling 226 shares, at $35.07 per share to cover tax obligations, leaving Peng with 65,405 shares held directly.

Pharvaris N.V. director Johannes Gerardus Christiaan Petrus Schikan reported open-market sales of company common stock under a pre-arranged Rule 10b5-1 trading plan. He sold 6,888 shares on June 29, 2026 at a weighted average price of $35.0533 per share and 30,712 shares on June 30, 2026 at a weighted average price of $35.4926 per share.

Following these transactions, he directly holds 315,167 Pharvaris common shares. Footnotes state that both sales were executed through multiple trades within daily price ranges of $35.00–$35.10 and $35.00–$35.90, respectively, and were carried out pursuant to his Rule 10b5-1 trading plan.

Pharvaris N.V. executive Anne Lesage, Chief Early Development, reported a mix of stock option exercises and share sales in Pharvaris common stock. She exercised options to acquire 37,572 shares at strike prices of $8.05 and $2.59 per share, then sold 76,172 shares in open-market transactions at weighted average prices around $35 per share. The filing states these were scheduled transactions under a Rule 10b5-1 trading plan and involved cashless exercise of options. After the transactions, she holds 58,750 shares directly and 93,969 shares indirectly through GrayMatters Consulting B.V., an entity she controls.

Pharvaris N.V. executive Anne Lesage, Chief Early Development, reported a scheduled option exercise and share sale on June 25, 2026 under a Rule 10b5-1 trading plan.

She sold 2,300 Pharvaris common shares indirectly through GrayMatters Consulting B.V. and 2,300 shares directly in open‑market transactions at weighted average prices of $35.1242 and $35.1194 per share. The sales were linked to a cashless exercise of stock options for 900 shares at $8.05 and 1,400 shares at $2.59 per share. Following these transactions, Lesage holds 56,450 common shares directly and 131,669 shares indirectly through GrayMatters, while option grants continue to vest over time as disclosed.

Pharvaris N.V. director Johannes Gerardus Christiaan Petrus Schikan reported an open-market sale of 2,400 shares of common stock. The shares were sold at a weighted average price of $35.1041 per share under a pre-arranged Rule 10b5-1 trading plan, with individual trade prices ranging from $35.00 to $35.30. After this transaction, Schikan directly holds 352,767 shares of Pharvaris common stock.

Pharvaris N.V. Chief Medical Officer Lu Peng reported a series of option exercises and related share sales. On June 25–26, 2026, she exercised stock options covering 29,700 shares of common stock at a $2.59 exercise price and sold 29,700 shares in open-market transactions under a Rule 10b5-1 trading plan using cashless exercises. Reported weighted average sale prices were about $34.45, $35.09, and $34.00, each reflecting multiple trades within narrow price ranges. Following these transactions, Peng holds 65,631 shares of Pharvaris common stock directly.

Pharvaris N.V.’s Chief Medical Officer Lu Peng reported a small, scheduled option exercise and share sale. On June 18, 2026, Peng exercised stock options to acquire 300 shares of common stock at $2.59 per share and sold 300 common shares at $34.00 per share in an open-market transaction.

The filing states this was done under a Rule 10b5-1 trading plan. After these transactions, Peng directly holds 65,631 common shares and 205,008 stock options with a $2.59 exercise price expiring on February 3, 2030, indicating the sale involved only a small portion of the overall position.

Pharvaris N.V. director and Chief Executive Officer Berndt Modig reported small open-market sales of company common stock. On June 15, 2026, he sold a total of 2,291 shares in two transactions at weighted average prices of about $31.05 and $31.46 per share, executed under a Rule 10b5-1 trading plan. The filing notes that the sold shares included stock previously acquired through vesting of restricted stock units. Following these sales, Modig holds 135,209 shares directly and 950,000 shares indirectly through Schoodic Management BV, an entity he controls.

Pharvaris N.V. Chief Medical Officer Lu Peng had 117 shares of Common Stock withheld on June 12, 2026 to cover tax obligations from vesting restricted stock units. The shares were valued at $32.20 each based on fair market value, and Peng now directly holds 65,631 shares.

Pharvaris N.V. Chief Medical Officer Lu Peng reported a small share disposition tied to equity compensation. On the vesting of restricted stock units on June 11, 2026, 109 shares of common stock were withheld to cover tax withholding obligations at a fair market value of $31.51 per share. After this tax-withholding event, Lu Peng directly owns 65,748 shares of Pharvaris common stock, so the filing reflects routine administration of stock-based compensation rather than an open-market trade.

Pharvaris N.V. principal accounting officer Anna Nijdam sold 2,670 shares of common stock in an open-market transaction on June 4, 2026, at a weighted average price of about $30.87 per share. The shares sold were acquired upon vesting of restricted stock units, and she continues to hold 46,275 shares directly after the sale.

Pharvaris N.V. director Viviane Monges sold 9,667 shares of Common Stock in an open-market transaction. The sale occurred on May 21, 2026 at a weighted average price of $30.2941 per share, with individual trade prices ranging from $30.08 to $30.49 per share.

The shares sold were previously acquired upon vesting of restricted stock units granted as equity compensation. Following this transaction, Monges directly holds 5,500 Pharvaris shares. A footnote also corrects prior beneficial ownership reported on a Form 3, which had understated holdings by 513 shares due to earlier administrative errors in tax-withholding records.

Pharvaris N.V. insider activity centers on an option exercise paired with share sales. Principal Accounting Officer Anna Nijdam exercised stock options to acquire 7,330 shares of Common Stock at $20.00 per share, then sold the same number of shares in open-market, cashless transactions on May 21–22, 2026 at weighted average prices around $30.60–$30.74 per share.

Following these transactions, she directly owns 48,945 Common Stock shares. The filing also corrects a prior RSU vesting report, clarifying that total beneficial ownership as of April 11, 2026 should have been 48,945 shares, five more than previously reported due to an overstated tax withholding amount.

Pharvaris N.V. CFO/CLO David W. Nassif reported an open-market sale of 10,000 shares of Common Stock at a weighted average price of $30.3076 per share. The shares sold were previously acquired upon vesting of restricted stock units. Following this transaction, he directly holds 120,300 shares. The filing also corrects a prior Form 3 that understated his beneficial ownership by 6,375 shares due to an administrative error in tax-withholding reporting.

Pharvaris N.V. director Elisabeth Bjork executed a scheduled option exercise and share sale under a Rule 10b5-1 trading plan. She exercised stock options for 10,000 common shares at $8.05 per share in a cashless transaction and sold 10,000 common shares at a weighted average price of $29.3166, with individual sale prices ranging from $29.03 to $29.61. Following these transactions, she holds 15,167 common shares and 11,000 stock options, which expire on April 6, 2033. The option grant vested 25% on April 6, 2024, with the remaining shares vesting in equal monthly installments thereafter.

Pharvaris N.V. director and Chief Executive Officer Berndt Modig filed an amended Form 4 to update his reported shareholdings. The amendment adds previously omitted indirect holdings and does not change any transactions.

After this update, he is shown as holding 950,000 shares of Common Stock indirectly through Schoodic Management BV and 137,500 shares directly. The filing clarifies ownership totals rather than reporting new buys or sells.

Pharvaris N.V.’s Chief Executive Officer, Berndt Modig, sold 2,292 shares of common stock in an open-market transaction. The sale on May 18, 2026 was executed at a weighted average price of $29.222 per share under a Rule 10b5-1 trading plan.

Following this transaction, Modig directly holds 137,500 shares of Pharvaris common stock. The footnote explains that the sold shares include stock previously acquired upon vesting of restricted stock units, and that individual sale prices ranged from $29.47 to $30.40.

Pharvaris N.V. director Robert Glassman reported an exercise-and-sell transaction in company stock. On May 15, 2026, he exercised stock options for 5,333 shares of common stock at a price of $22.31 per share, then sold a total of 10,000 shares in open-market transactions at weighted average prices around $29.82 per share. The sales were executed in multiple trades within price ranges disclosed in the footnotes, and his directly held stake after the transactions was 10,500 common shares. The option exercised was fully vested as of April 11, 2025.

Pharvaris N.V. Chief Technical Ops Officer Stefan Andreas Abele reported an open-market sale of common stock. He sold 8,748 shares at an average price of $29.8199 per share. After the transaction, he directly holds 35,194 shares.

The reported holdings include shares of common stock that were previously acquired upon vesting of restricted stock units on various dates, according to the accompanying footnote.

Pharvaris N.V. Chief Commercial Officer Wim Souverijns sold 10,000 shares of Common Stock in an open-market transaction at a weighted average price of $29.9163 per share. The sale was executed on May 15, 2026 under a pre-arranged Rule 10b5-1 trading plan, and Souverijns held 45,111 shares after the transaction.

Pharvaris N.V. Chief Medical Officer Lu Peng reported tax-withholding dispositions of 226 shares of Common Stock connected to restricted stock unit vesting on May 11 and May 12, 2026. On those dates, 109 shares were withheld at $30.09 per share and 117 shares at $29.95 per share to satisfy tax obligations, leaving him with 65,857 shares held directly.

Pharvaris N.V. Chief Medical Officer Lu Peng reported an exercise-and-sale transaction in company stock. On May 1, 2026, Peng exercised stock options to acquire 14,166 shares of common stock at an exercise price of $2.59 per share, then sold the same number of shares in open-market trades under a pre-arranged Rule 10b5-1 trading plan. The sales, executed as a cashless exercise, had weighted average prices around $30–$31 per share. Following these transactions, Peng directly holds 66,083 shares of Pharvaris common stock.

Pharvaris N.V. director Johannes Schikan reported open-market sales of a total of 32,900 shares of common stock. The sales occurred on April 29–30 at weighted average prices of $30.07, $30.30, and $31.03 per share under a pre-set Rule 10b5-1 trading plan. After these transactions, he directly holds 355,167 shares, indicating the sales represent a relatively small portion of his overall position and appear to be routine, pre-planned disposals rather than discretionary trades.

Pharvaris N.V. executive Anne Lesage, Chief Early Development, reported a mix of stock option exercises and open-market sales in Pharvaris common stock. Over two days, she exercised 25,400 shares through stock options at exercise prices of $8.05 and $2.59 per share and sold 48,300 shares in open-market transactions under a pre-arranged Rule 10b5-1 trading plan.

Following these transactions, the filing shows Lesage holding 56,450 Pharvaris common shares directly and 133,969 shares indirectly through GrayMatters Consulting B.V., an entity she controls. Remaining stock options include 82,000 options with an $8.05 exercise price and 9,072 options with a $2.59 exercise price.

Lu Peng, Chief Medical Officer of Pharvaris N.V., reported an exercise-and-sale sequence under a Rule 10b5-1 trading plan. Peng exercised options to acquire 18,733 shares of common stock at $2.59 per share and sold the same number of shares in open-market transactions at weighted average prices around $30 on April 29–30, 2026.

Following these transactions, Peng directly holds 66,083 shares of Pharvaris common stock and 219,474 stock options from the referenced grant, which remains outstanding until February 3, 2030.

Pharvaris N.V. director Johannes Schikan reported open-market sales of 7,100 shares of Common Stock in two transactions. He sold 7,000 shares on April 22, 2026 at $30.0541 per share and 100 shares on April 23, 2026 at $30.03 per share, under a pre-planned Rule 10b5-1 trading plan. Following these sales, he directly holds 388,067 Pharvaris shares.

Pharvaris N.V. Chief Early Development officer Anne Lesage reported a combination of stock option exercises and share sales in Pharvaris common stock. On April 22–23, 2026, she exercised 7,600 stock options and sold 14,700 common shares in open-market transactions at prices around $30 per share, as part of a Rule 10b5-1 trading plan.

Following these transactions, Lesage holds 56,450 Pharvaris shares directly and 156,869 shares indirectly through GrayMatters Consulting B.V. The exercised options carried strike prices of $8.05 and $2.59 and were originally subject to multi-year vesting schedules.

Pharvaris N.V. Chief Medical Officer Lu Peng executed a small, pre-planned option exercise-and-sell transaction under a Rule 10b5-1 trading plan. On April 22–23, 2026, Peng exercised options to acquire 7,101 shares of common stock at $2.59 per share and sold the same 7,101 shares in open-market transactions around $30 per share.

After these trades, Peng directly holds 66,083 shares of common stock and 106,207 stock options expiring in 2030. The filing characterizes the activity as a scheduled transaction pursuant to a Rule 10b5-1 trading plan, indicating it was arranged in advance rather than timed opportunistically.

Pharvaris N.V. Chief Medical Officer Lu Peng reported a routine tax-related share withholding. On April 16, 2026, 226 common shares were disposed of at a fair market value of $28.78 per share to satisfy tax withholding obligations from restricted stock units that vested on April 11 and April 12, 2026. After this non‑market transaction, Lu Peng directly held 66,083 common shares.

Pharvaris N.V. Chief Executive Officer Berndt Modig reported a small open-market sale of company stock. On April 16, 2026, he sold 2,292 shares of Pharvaris common stock at a weighted average price of $28.6032 per share in a series of trades executed under a Rule 10b5-1 trading plan. These sales involved shares that include stock previously acquired upon vesting of restricted stock units. After the sale, he directly owns 139,792 shares of common stock and also has an indirect holding of 950,000 shares through Schoodic Management BV, an entity he controls, indicating he retains a substantial overall stake in the company.

Pharvaris N.V. Principal Accounting Officer Anna Nijdam reported a routine tax-related share disposition. On the vesting of restricted stock units, the issuer withheld 548 shares of common stock at $26.63 per share to cover tax withholding obligations. After this withholding, Nijdam directly holds 48,940 common shares.

Pharvaris N.V. Chief Executive Officer Berndt Modig reported open-market sales of a total of 23,333 shares of common stock on April 9, 2026. The transactions were executed under a Rule 10b5-1 trading plan at weighted average prices of $27.7352 and $28.415 per share, across price ranges of $27.31–$28.30 and $28.32–$28.51. The shares sold include stock previously acquired upon vesting of restricted stock units. Following these sales, Modig holds 142,084 shares directly and 950,000 shares indirectly through Schoodif Management BV.

Pharvaris N.V. Principal Accounting Officer Anna Nijdam had 1,167 shares of Common Stock withheld by the company at $28.56 per share to cover tax obligations upon the vesting of restricted stock units. After this tax-withholding disposition, she directly holds 49,488 shares.

Pharvaris N.V.’s Principal Accounting Officer Anna Nijdam reported a routine tax-related share disposition. On the vesting of restricted stock units, 1,164 shares of common stock were withheld by the company at $28.25 per share to cover tax withholding obligations. After this withholding, Nijdam directly holds 50,655 shares of Pharvaris common stock. This was not an open-market sale but an administrative step tied to equity compensation.